EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...
Background The National Heart Failure Audit gathers data on patients coded at discharge (or death) as having heart failure as ...
Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...
Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...
Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.
Doctors often say labs look “normal.” Dr. Mark Hyman explains why that doesn’t always reflect wellness, and what early ...
At its December meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Aumseqa (aumolertinib mesylate, SFL Pharmaceuticals ...
Organs often have fluid-filled spaces called lumens, which are crucial for organ function and serve as transport and delivery ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Woman's World on MSN
Normal AST levels by age: Are you at risk of fatty liver disease?
A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback